MIAMI - Pulse Biosciences, Inc. (NASDAQ:PLSE), a biotech company with a market capitalization of $1.08 billion and an ...

Researchers evaluated a drug that represents a new class of anticoagulants known as Factor XI inhibitors for treating patients with atrial fibrillation as part of the AZALEA-TIMI 71 Study. The trial ...

Atrial fibrillation (AF) is the most common abnormal heart rhythm affecting 6 million people in the USA and can cause strokes and heart failure. Conventional treatments are successful but may need to ...

Patients with atrial fibrillation are typically prescribed an anticoagulant, or blood thinner, to reduce the risk of stroke, but many may discontinue them or never receive a prescription due to ...

The Ordensklinikum Linz Elisabethinen is one of the first centers worldwide and the first center in Austria to use a new method for the treatment of ...

(THE CONVERSATION) Atrial fibrillation, or A-fib, is an irregular heart rhythm that increases a person’s risk of stroke, heart failure and even premature death. While many risk factors contribute to A ...

CardioFocus, Inc., a medical device company dedicated to advancing ablation treatment for cardiac arrhythmias, today ...

Our Lady of Lourdes Regional Medical Center is embracing cutting-edge technology to transform how heart conditions are ...

Boston Scientific Corporation (NYSE: BSX) today announced data supporting the use of the FARAPULSE™ Pulsed Field Ablation ...